{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"CTA up-regulation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CD138+ cells"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"unfractionated bone marrow"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"CTA (CTAG1B)-specific T cell response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.","groups":[{"description":"azacitidine: 75 mg/sq m daily for 5 days\n\nlenalidomide: 10 mg p.o. daily, Days 6-21","id":"OG000","title":"5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 months","title":"CTA Expression Before and After Azacitidine Therapy","type":"SECONDARY","unitOfMeasure":"participants"}